Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline
Pharmacology, Toxicology and Pharmaceutical Science
2
3%
Business, Management and Accounting
1
1%
Other
4
6%
Unknown
47
66%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2024.
All research outputs
#5,097,755
of 26,404,318 outputs
Outputs from BMJ Open Diabetes Research & Care
#355
of 1,106 outputs
Outputs of similar age
#119,406
of 532,358 outputs
Outputs of similar age from BMJ Open Diabetes Research & Care
#11
of 46 outputs
Altmetric has tracked 26,404,318 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,106 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.6. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 532,358 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
